ASO Author Reflections: Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) of Extraperitoneal Abdominal Disease, a Likely Common Practice but Infrequently Reported

The genesis of peritoneal surface malignancy (PSM) surgery dates back to the late 1920s with Dr. Meig's pioneering work evaluating cytoreductive surgery (CRS) with ovarian cancer.Advances in CRS were achieved by surgeons such as Dr. Griffith at the National Cancer Institute and Dr. Long at the University of Alabama expanding the scope of CRS.Dr. Sugarbaker is primarily accredited for combining hyperthermic intraperitoneal chemotherapy (HIPEC) with CRS into the modern practice of PSM surgery.Randomized control trials led by Dr. Verwaal and Dr. Cashin as well as the most recent PRODIGE7 trial have validated CRS-HIPEC as standard-of-care therapy for PSM.This foundational research and these landmarks trials are rooted in the premise that CRS-HIPEC is effective only when disease is limited to the peritoneal cavity.